PFE
AI Execution Plan
Positive Phase 2b obesity drug results (12.3% weight loss); Q4 2025 revenue $62.6B; Mixed analyst reactions to outlook and data; Novo notes competition; Recent Neutral rating PT 27.
Overall neutral per TradingView; MACD positive (0.06 Buy per Investing.com); Above 5-day MA 26.41 (Buy); Recent rally indicates short-term momentum building.
3-Month AI Outlook
Bullish. Obesity drug pipeline progress, high dividend yield, low fwd PE, analyst avg target 28.74 offer upside to 30+. Monitor earnings execution and patent risks.
Option Chain
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
Earnings History: PFE
Pfizer Reports Strong Second-Quarter 2025 Results and Raises EPS Guidance
Aug 5, 2025Pfizer Inc. reported second-quarter 2025 revenues of $14.7 billion, reflecting a 10% increase compared to the same period last year. The company achieved a reported net income of $2.91 billion, with a reported diluted earnings per share (EPS) of $0.51 and an adjusted diluted EPS of $0.78. Pfizer reaffirmed its 2025 revenue guidance in the range of $61.0 to $64.0 billion and raised its adjusted diluted EPS guidance by $0.10 to a new range of $2.90 to $3.10. Research and development (R&D) expenses for the quarter totaled $2.48 billion, representing an 8% decrease compared to the previous year. Pfizer is on track to achieve approximately $7.2 billion in net cost savings from previously announced cost improvement initiatives by the end of 2027, which is expected to enhance productivity and operating margins. In product development, Pfizer announced significant advancements, including positive results from the Phase 3 BREAKWATER trial for Braftovi in metastatic colorectal cancer, and the European Medicines Agency's recommendation for marketing authorization of its updated COVID-19 vaccine targeting the LP.8.1 variant. Additionally, the company completed a significant licensing agreement with 3SBio, Inc. to develop a bispecific antibody for various cancers, which involves an upfront payment of $1.25 billion. Pfizer returned $4.9 billion to shareholders in cash dividends during the first half of 2025, with no share repurchases completed to date. The company plans to maintain a balanced capital allocation strategy, focusing on reinvestment in growth opportunities while managing its leverage.
Strategy Overview
Jason Wheel is a systematic, AI‑enhanced trading framework built on probability theory and volatility‑based edge extraction. Designed for the US options market, the system focuses on constructing high‑probability Credit Spread strategies that capture Theta decay while maintaining strict quantitative risk controls to mitigate tail events and support long‑term, stable capital growth.
Rather than relying on directional speculation, the system operates as a closed‑loop asset engine integrating: Macro Risk Control, Multi-dimensional Quantitative Screening, AI-Assisted Decision Making, and Dynamic Position Management.
This architecture enables consistent, rules‑driven execution with an emphasis on risk‑adjusted returns.
Connect with Jason
- Substack: jasonwheel.substack.com
- Email: [email protected]